Chemotherapy News and Research

Latest Chemotherapy News and Research

AVEO announces results from tivozanib Phase 1b clinical trial for advanced gastrointestinal cancers

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced results from a Phase 1b clinical trial evaluating the company's lead product candidate, tivozanib, a highly potent and selective inhibitor of VEGF receptors 1, 2, and 3, in combination with FOLFOX6, a standard chemotherapy regimen, in patients with advanced gastrointestinal (GI) cancers.

19 Nov 2010

OXiGENE updates data on FALCON trial for non-small cell lung cancer

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it presented updated safety and clinical activity data from the FALCON trial, a randomized, controlled Phase 2 study of ZYBRESTAT(TM) (CA4P) in patients with non-small cell lung cancer (NSCLC).

19 Nov 2010

Spectrum to present four key belinostat data for solid cancers at ASH annual meeting

Spectrum Pharmaceuticals, Inc., a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced four key belinostat data presentations at the 52nd Annual Meeting of the American Society of Hematology (ASH), being held at the Orange County Convention Center in Orlando, Florida, December 4-7, 2010.

19 Nov 2010

Expert panel to endorse newly approved therapeutic vaccine for advanced prostate cancer

Provenge is one step closer to being covered by Medicare. An expert panel voted Wednesday to endorse the newly approved therapeutic vaccine for men with advanced prostate cancer.

19 Nov 2010

Aeterna presents data on AEZS-108 Phase 2 study for endometrial cancer at EORTC-NCI-AACR Symposium

Aeterna Zentaris Inc., earlier today, presented Phase 2 positive efficacy and safety data for its compound, AEZS-108, in advanced endometrial cancer.

18 Nov 2010

Yorkshire scientist wins national medical award for surgical improvement in colon cancer

A Yorkshire Cancer Research scientist has earned himself a national medical award for helping pioneer life-saving surgical improvements to the way tumours are removed from colon cancer patients.

18 Nov 2010

New anti-cancer drug targeting vitamin D receptor reduces PSA level in HRPC

A new anti-cancer drug aimed at vitamin D receptors on cancer cells has prompted encouraging responses in the levels of PSA (prostate specific antigen) in men with prostate cancer that has become resistant to hormonal therapies.

18 Nov 2010

MK-4827 drug candidate shows promising anti-tumour activity in first human trial

A new drug that targets proteins responsible for helping cancer cells to repair damage to their DNA has shown promising anti-tumour activity in its first trial in humans.

18 Nov 2010

Exelixis reports interim data of XL184 for metastatic castration-resistant prostate cancer

Exelixis, Inc. today reported interim data from the cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with XL184 in an ongoing phase 2 adaptive randomized discontinuation trial (RDT).

18 Nov 2010

Study shows end-of-life care varies widely

A new study released by the Dartmouth Atlas of Health Care finds that "America's hospitals treat patients with life-ending cancers very differently in their final months, with some deploying chemotherapy and other life-prolonging efforts until the end and others directing most of their patients into hospice," reports Kaiser Health News. The aggressive care may not be best for patients, and hospice may be a "more humane way to die," the report argues. A point the report doesn't address: that aggressive treatment "also adds to the drain on Medicare's pocketbook."

18 Nov 2010

Hospice or hospital? Where you die depends on where you live

America's hospitals treat patients with life-ending cancers very differently in their final months, with some deploying chemotherapy and other life-prolonging efforts until the end and others directing most of their patients into hospice, a new study finds.

18 Nov 2010

MedImmune to present data on oncology portfolio at two medical congresses in Europe and the U.S.

Today, MedImmune announced that researchers will present data from its oncology portfolio, including new clinical data, at two upcoming medical congresses in Europe and the United States.

17 Nov 2010

Infinity announces enrollment in IPI-926 Phase 1b/2 clinical trial for pancreatic cancer

Infinity Pharmaceuticals, Inc. today announced that enrollment is ongoing locally for a Phase 1b/2 clinical trial of IPI-926, Infinity's oral molecule that inhibits Smoothened, a key component of the Hedgehog pathway, in combination with Gemzar (gemcitabine) in patients with previously untreated, metastatic pancreatic cancer.

17 Nov 2010

New OncoMap technique can detect point mutation in ovarian cancer

Researchers have shown that point mutations mis-spellings in a single letter of genetic code that drive the onset and growth of cancer cells can be detected successfully in advanced ovarian cancer using a technique called OncoMap. The finding opens the way for personalised medicine in which every patient could have their tumour screened, specific mutations identified, and the appropriate drug chosen to target the mutation and halt the growth of their cancer.

17 Nov 2010

Study: EGFR inhibtion may help treat triple negative breast cancer

Scientists believe they may have found a new target for treating triple negative breast cancer - one of the more difficult breast cancers to treat successfully and for which there is no targeted therapy at present.

17 Nov 2010

AVEO commences enrollment in Phase 1b combination trial of tivozanib with oral capecitabine in advanced tumors

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has initiated patient enrollment in an open-label, multi-center Phase 1b clinical trial evaluating tivozanib in combination with oral capecitabine (Xeloda®) in patients with certain advanced solid tumors.

17 Nov 2010

New mechanism breaks drug resistance in ovarian cancer

Drug resistance is a major obstacle in curing ovarian cancer but new research from the Centenary Institute has discovered a treatment that kills ovarian cancer cells in a new way that can break the resistance mechanism.

16 Nov 2010

4SC to present development of resminostat and preclinical drug candidates at EORTC-NCI-AACR symposium

4SC, a drug discovery and development company focused on autoimmune and cancer indications, today announced that it will present four posters and respective abstracts that highlight the development of its lead oncology compound resminostat and several preclinical drug candidates at the 22nd EORTC-NCI-AACR symposium from 16 - 19 November, 2010 in Berlin, Germany.

16 Nov 2010

New inhalable dry powder treatment for lung cancer shows significant increase in survival rates: Research

A new inhalable dry powder treatment for lung cancer shows a significant increase in survival rates and is far less invasive than current treatment options, which frequently include radiation and surgery. This research is being presented at the 2010 International Pharmaceutical Federation Pharmaceutical Sciences World Congress in association with the American Association of Pharmaceutical Scientists Annual Meeting and Exposition in New Orleans, La., Nov. 14-18.

16 Nov 2010

Infinity announces Phase 1b/2 clinical trial of IPI-926 in patients with metastatic pancreatic cancer

Infinity Pharmaceuticals, Inc. today announced that enrollment is ongoing locally for a Phase 1b/2 clinical trial of IPI-926, Infinity's oral molecule that inhibits Smoothened, a key component of the Hedgehog pathway, in combination with Gemzar (gemicitabine) in patients with previously untreated, metastatic pancreatic cancer.

16 Nov 2010

Chemotherapy News and Research

Latest Chemotherapy News and Research

AVEO announces results from tivozanib Phase 1b clinical trial for advanced gastrointestinal cancers

OXiGENE updates data on FALCON trial for non-small cell lung cancer

Spectrum to present four key belinostat data for solid cancers at ASH annual meeting

Expert panel to endorse newly approved therapeutic vaccine for advanced prostate cancer

Aeterna presents data on AEZS-108 Phase 2 study for endometrial cancer at EORTC-NCI-AACR Symposium

Yorkshire scientist wins national medical award for surgical improvement in colon cancer

New anti-cancer drug targeting vitamin D receptor reduces PSA level in HRPC

MK-4827 drug candidate shows promising anti-tumour activity in first human trial

Exelixis reports interim data of XL184 for metastatic castration-resistant prostate cancer

Study shows end-of-life care varies widely

Hospice or hospital? Where you die depends on where you live

MedImmune to present data on oncology portfolio at two medical congresses in Europe and the U.S.

Infinity announces enrollment in IPI-926 Phase 1b/2 clinical trial for pancreatic cancer

New OncoMap technique can detect point mutation in ovarian cancer

Study: EGFR inhibtion may help treat triple negative breast cancer

AVEO commences enrollment in Phase 1b combination trial of tivozanib with oral capecitabine in advanced tumors

New mechanism breaks drug resistance in ovarian cancer

4SC to present development of resminostat and preclinical drug candidates at EORTC-NCI-AACR symposium

New inhalable dry powder treatment for lung cancer shows significant increase in survival rates: Research

Infinity announces Phase 1b/2 clinical trial of IPI-926 in patients with metastatic pancreatic cancer

Cancer Research - Second Edition eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in